nature jobs.com - the premier science recruitment website

NPG's BioPartnering is dedicated to small and large companies looking for commercial partnerships and finding out more about licensing. Find executive profiles from companies actively looking for partners.

BioPharma Dealmakers

In a world where collaboration has become the key to drug discovery and development, Merck & Co., Inc., Whitehouse Station, NJ, stands out as an exceptionally committed partner to biotechs, venture capitalists, and academic researchers. One example is odanacatib, a candidate osteoporosis drug now in phase III, which Merck has been developing with Celera and its predecessors since 1996.

Crucell N.V.'s platform technologies are designed to speed up and simplify the development of antibodies, proteins and vaccines. As well as using them in-house to create innovative vaccines and therapeutics, Crucell provides access to its technologies, including its high-yielding human cell line technology PER.C6®, to biopharma companies, academic institutions, CMOs and CROs through flexible licensing agreements.

GSK increases its hunt for early stage biotech companies. We are looking for innovation wherever it may originate. Learn more on www.ceedd.com.


Avesthagen Limited, India's leading integrated systems biology platform company, is poised to make the transition from a research and development business to a product company. It is in position to make a global impression in the area of bioAgriculture, bioNutrition and biomarker markets and to provide a gateway into the Indian market for US and European companies. The company is now ready to take its product portfolio to the market in India and, with its partners, to the rest of the world.

Syngene, a subsidiary of Biocon Ltd, India's largest biotech company, has grown from 7 scientists in 1994 to more than 1250 employees spread across over a million square feet of infrastructure in 10 acres of area at Biocon Park, Bangalore and is generating revenues of more than $50 million.

TCG Lifesciences' consistent delivery of high value and complex medicinal chemistry solutions has made it a partner of choice. To date, TCG Lifesciences has established collaborations with 15 of the leading 20 global biopharmaceutical companies.

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, is seeking partners who will share the company's pursuit of innovation and drive for excellence. Our diverse culture and geography allow us to collaborate effectively with a broad array of partners around the world.

We are not only at the forefront of conquering newly targeted diseases, but also leading the way in expanding immunization across all age groups, including adolescents and the elderly. This leadership has translated into outstanding success in the industry, and our company has experienced a recent period of unprecedented growth.

PharmaLegacy is a new company postured to play a progressive role in China's fast-growing pharmaceutical contract resource industry.

Boehringer Ingelheim was manufacturing biotech products even before the Hungarian Engineer Károly (Karl) Ereky coined the term biotechnology (circa 1914). As early as 1895, the company's founder, Albert Boehringer, pioneered the use of bacteria to produce lactic acid. Today, Boehringer Ingelheim is a research driven pharmaceutical company that is also the largest contract manufacturing organization for biopharmaceutical production.

PharmaTelevision is an online TV channel targeting the biopharma industry. It offers interviews, comment, analysis, discussion and news on all aspects of the sector. PharmaTelevision is part of PharmaVentures, which provides consultancy, advice and support in all aspects of deal making to pharmaceutical and biotechnology companies.

Phylomer® libraries: the most structurally diverse libraries available for discovery of high quality peptide leads targeting protein interactions.

 

DBV Technologies (DBV) is a company focused on non-invasive epicutaneous drug delivery. Its patented technology platform VIASKIN® uses electrostatic forces to deliver compounds non-invasively to the epidermis without disrupting the blood-skin barrier. VIASKIN®; has a broad applicability across allergy diagnostics, specific immunotherapy, vaccine delivery and cosmaceuticals. DBV is currently seeking partners in these areas.

arGEN-X's SIMPLE Antibody™ platform generates an unparalleled functional diversity of human antibody leads which routinely exhibit gold-standard affinities, potencies and expression levels...

 

DesignMedix develops novel pharmaceutical products for the treatment and prevention of life- threatening infectious diseases using its proprietary approach to overcoming drug resistance.

BioQuanta's Science as a service platforms provide world class results applying Lean discovery processes within the translational research approach. We are committed to delivering the best by providing innovative and safer tools for maximal R&D efficiency.

Teva Pharmaceutical Industries Ltd is probably better known as one of the largest generic pharmaceutical companies in the world but it does have a growing interest in in-licensing medicines that can be used by specialist clinicians from both biotech and academic sources. Historically, it has sourced its innovative assets from within Israel but it is now looking to access innovative, pre-clinical programs from U.S. and European sources.

Biological drug development is an expensive process, and companies developing therapeutics look to save money at every stage. However, according to SynCo Bio Partners, investing in planning process development early in the drug development cycle could save money and time at a later stage, and could even mean the difference between marketing approval and rejection.

Formed as a spin-out company from Grupo Uriach's research and development unit in November 2006, Palau Pharma S.A. focuses on the development of innovative small molecule therapeutics from discovery to clinical proof-of-concept for the treatment of inflammatory and autoimmune diseases in areas of unmet medical need.

HUNT Biosciences is the commercial arm of the HUNT Databank, one of the world's most comprehensive population-based prospective health surveys and biobanks.

Novo Nordisk seeks partners to increase its promising, protein-based pipeline within diabetes, haemostasis and chronic inflammation. Novo Nordisk masters all aspects of bringing proteins from molecule to market, and employs more than 25,000 staff in 79 countries worldwide.

 
 

The Health Protection Agency's core business areas are research and development of vaccines against infectious diseases, process development and GMP manufacture of biologics. In addition, a wide range of support services are offered from biosafety, through GLP immunoassay testing to in vivo studies.

BTG in-licenses, develops and commercialises pharmaceuticals. Principally in the field of neuroscience but also in other areas. The company has a substantial and growing revenue stream of royalties from out licensed products and a broad, expanding internal pipeline of development programmes. This company is evolving towards growing a later stage pipeline, eventually aiming to take niche products to market. This will be funded by milestones and royalties from partnered programs, including two projects in Phase III and seven in Phase II.

Institut Pasteur acknowledges that the best performers in the Pharma Industry have shifted from focused collaborations with academia to more widely open research programs with centers of excellence.

We have gathered a special purpose team to define with each company the research collaborations needed to find solutions to knowledge deadlocks in product development programs.

Antisense Pharma focuses on the development of gene silencing therapies against highly malignant cancers. We identify and develop antisense drugs, which specifically down-regulate key cancer mediating proteins. Our lead compound AP 12009 is in advanced clinical development stage for high-grade glioma (Phase IIb completed) and other solid tumors and is available for worldwide partnering.

Open for Business - Imperial offers unique opportunities to enhance innovation in R&D through collaborative research, technology licensing and consulting - current partners include major healthcare, biotech and pharmaceutical companies in a wide range of deal-structures. Deal-making support is provided by the BioPharma Business Development team led by Dominique Kleyn.

UCL Business is the access point to the wealth of innovation and intellectual property emanating from UCL, and we offer a number of services to assist the technology transfer process, from consultancy through to collaborative research, IP licensing and the creation of spinout companies and joint ventures to maximise the commercial potential of new discoveries, materials and processes.

Affitech discovers and develops fully human antibody therapeutics for both partners, such as Roche and Peregrine, and its own pipeline with a primary focus in oncology. Headquartered in Oslo, Norway with business development in San Francisco, California, Affitech uses two proprietary discovery technologies - MBAS (molecule based) and CBAS(cell based). By discovering both antibody and target simultaneously from patient libraries CBAS shortens development times by up to two years.

Debiopharm is a financially independent drug development company based in Lausanne, Switzerland, that in-licenses promising therapeutic compounds, develops them globally and then out-licenses them for commercialization. By concentrating only on the development of products rather than on external investors and sales and marketing, Debiopharm has become a highly successful developer.

VIA Pharmaceuticals, Inc. is a biotechnology company located in San Francisco, California, which is focused on the development of therapeutics for the treatment of cardiovascular disease. Its lead compound, VIA-2291, is currently in Phase II clinical trials in North America and Europe. It targets inflammation in the blood vessel, the underlying cause of cardiovascular disease.

  • Advertising Profiles
    For more information about BioPharma Dealmakers or to purchase an Advertising Profile please contact:
    Graham Combe
    Business Development, BioPharma
    Email: g.combe@nature.com
    Telephone: +44 (0)20 7843 4914

Partnering Features

Pharmas are making smaller deals
Small biotech has the goods

Download Article

 

 

Pharma's Predicament is Biotech's Bonanza
Patent expirations are on the verge of creating giant gaps in pharma revenue streams, and in this feature from May '09 BioPharma Dealmakers, writer George Mack believes the mega-merger approach is only a temporary solution. A new approach is needed, let the new era for biotech begin in earnest.

Download Article

 

 

The Right Stuff
Despite global economic woes, the biopharmaceutical industry's intrinsic value continues to build. In the October'08 edition of BioPharma Dealmakers, freelance journalist Crispin Littlehales looks into the latest strategies of the most prolific dealmakers in the biopharma industry? A range of different organizations, from universities to biotech and pharma companies, provide their views on the global partnering outlook.

Download Article

 

 

No Guts No Glory
When the going get's tough, the tough get going! In this article from the June'08 Licensing Executive Profiles, freelance journalist Crispin Littlehales interviews some of the industry's leading Dealmakers. Through this we see some of the most courageous partnering strategies from the major players, giving insight into how the marketplace is shaping up.

Download Article

 

 

Let's make a Deal
In this article from the October'07 Licensing Executive Profiles, freelance journalist Crispin Littlehales analyzes the global biopartnering marketplace. Here you can glean insight from some of the most prolific biopartnering deal makers, who indicate what it is the major pharmaceutical and biotech companies are looking for from potential biotech collaborators.

Download Article

 

 

ADVERTISEMENT